| Japanese |
|---|
| Title | 関東甲信越地区における99mTc標識心筋血流製剤の使用状況 |
|---|
| Subtitle | 資料 |
|---|
| Authors | 心臓核医学談話会, 橋本順, 田中健, 佐々木康人, 村田啓, 久保敦司, 今井嘉門, 大鈴文孝, 大嶽達, 廣江道昭, 中川晋, 丸野広大, 山崎純一 |
|---|
| Authors(kana) | |
|---|
| Organization | |
|---|
| Journal | 核医学 |
|---|
| Volume | 35 |
|---|
| Number | 6 |
|---|
| Page | 443-450 |
|---|
| Year/Month | 1998/7 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」99mTc標識心筋血流製剤の利用状況を調査する目的で, 関東甲信越地方の施設を対象にアンケート調査を行ったところ, 83施設から回答が得られた. 201Tlよりも99mTc製剤を多く使用している施設は83施設中10施設のみであった. 99mTc製剤を使用しない理由としては, 2回の投与が面倒であること, 201Tlは viability の評価に優れ, 過去のデータの蓄積が豊富であること, 99mTc製剤では腹部臓器への集積が高いことなどが挙げられた. 検査目的では201Tl検査にくらべて viability の判断を目的とする割合が少なく, 虚血の検出を目的とする割合が多かった. 心筋血流と壁運動の同時評価や201Tlと99mTc血流製剤を用いた2核種同時収集といった99mTc製剤の利点を活かした検査方法の有用性を指摘する意見がみられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc-MIBI, 99mTc-tetrofosmin, Clinical use |
|---|
| English |
|---|
| Title | Use of 99mTc-labeled Myocardial Perfusion Agents in the Kanto-Koshinetsu Area |
|---|
| Subtitle | |
|---|
| Authors | Jun HASHIMOTO, Takeshi TANAKA, Yasuhito SASAKI, Hajime MURATA, Atsushi KUBO, Kamon IMAI, Fumitaka OSUZU, Tohru OTAKE, Michiaki HIROE, Susumu NAKAGAWA, Hirotaka MARUNO, Junichi YAMAZAKI |
|---|
| Authors(kana) | |
|---|
| Organization | Nuclear Cardiology Forum |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 35 |
|---|
| Number | 6 |
|---|
| Page | 443-450 |
|---|
| Year/Month | 1998/7 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | We sent out a questionnaire to investigate how the 99mTc-labeled myocardial perfusion agents are used in the Kanto-Koshinetsu area. Answers were obtained from 83 laboratories. Examinations using 99mTc-labeled agents were performed more frequently than those using 201Tl only in 10 of 83 laboratories. Main reasons for not using 99mTc-labeled agents were as follows: two injections required in the stress study, superiority of thallium-201 in the assessment of myocardial viability, a large amount of clinical data cumulated in thallium-201 imaging, and problems caused by abdominal uptake of 99mTc-labeled agents. Comparing purposes of the examinations using 201Tl and 99mTc-labeled agents, evaluation of myocardial viability was more common in 201Tl imaging, meanwhile, detection of myocardial ischemia was more common in imaging with 99mTc-labeled agents. It was pointed out that dual isotope imaging using 201Tl and 99mTc-labeled agents and simultaneous evaluation of myocardial perfusion and cardiac function are clinically feasible as new diagnostic procedures. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc-MIBI, 99mTc-tetrofosmin, Clinical use |
|---|